3rd Quarter - Report

BROWNSTEIN HYATT FARBER SCHRECK, LLP for BAXTER HEALTHCARE CORPORATION

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$30,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 19, 2017 $30,000 Replaced
3rd Quarter - Amendment Oct 5, 2019 $30,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Funding issues for Medicare Part B 340 B drug discount program

LobbyistCovered position, as disclosed
CATE MCCANLESS BLANKENBURG —
LAURA JOHNSON BOLLIER —
ALEXANDER DAHL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Health Issues HCR

Healthcare reform In-home dialysis Telemedicine Availability of medical products H.R. 1245 - Affordable and Safe Prescription Drug Importation Act S. 934/H.R. 2430 - FDA Reauthorization Act of 2017

LobbyistCovered position, as disclosed
CATE MCCANLESS BLANKENBURG —
LAURA JOHNSON BOLLIER —
ALEXANDER DAHL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 934 (115th), H.R. 2430 (115th), H.R. 1245 (115th)

Taxation/Internal Revenue Code TAX

Corporate tax issues, including deferral and device tax Tax reform Issues related to the border adjustment tax

LobbyistCovered position, as disclosed
ALEXANDER DAHL —
LORI HARJU —
MICHAEL B LEVY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.